Scientists in Europe have added their voices to the many thousands of objections made against proposed changes to the oversight of U.S. federal research grants, under which political appointees and not peer review experts would have the final say on who and what gets funding. The concern is that awarding grants, based on the principle that research proposals must be in keeping with President Donald Trump’s policy priorities, poses a threat to open scientific inquiry and academic freedom, and also will undermine international research collaboration.

An increase in the level of M&A activity and some sizeable financing rounds are encouraging signs for the med-tech investment environment, said Joey Mason, life sciences venture partner at Claret Capital Partners. He pointed to Medtronic plc’s acquisition of SPR Therapeutics Inc., and Neurent Medical Ltd.’s large fundraise earlier in the year, as evidence of the improving sentiment.

Scientists in Europe have added their voices to the many thousands of objections made against proposed changes to the oversight of U.S. federal research grants, under which political appointees and not peer review experts would have the final say on who and what gets funding. The concern is that awarding grants, based on the principle that research proposals must be in keeping with President Donald Trump’s policy priorities, poses a threat to open scientific inquiry and academic freedom, and also will undermine international research collaboration.

AMT Medical BV reported positive one-year data from a study looking at its ELANA device, a sutureless coronary bypass technology designed to simplify one of the most technically demanding steps in coronary artery bypass grafting, and potentially expand use of the minimally invasive procedures.

U.K. biotech has recorded the strongest quarter for venture capital raised in five years, with companies attracting £2.05 billion (US$3.36 billion) in the second quarter (Q2) of 2026. While that figure is dominated by the £1.56 billion series B round raised by Google Deepmind’s AI drug discovery spin-off Isomorphic Labs Ltd, the remaining £498 million is a significant increase to the £279 million raised in Q2 of 2025.

Leica Biosystems GmbH, agreed to buy Statlab Medical Products in a move that will strengthen parent company Danaher Corp.'s diagnostics and anatomical pathology portfolio with a broader range of consumables and instruments. Although the financial terms were not disclosed, RBC Capital Markets analyst Dan Leonard reckoned that the deal could be valued at more than $1 billion.

GSK plc’s walk-away from refractory chronic cough prospect camlipixant because of dicey phase III results opened the door wider for Trevi Therapeutics Inc. with Haduvio (oral nalbuphine ER), which yielded positive phase II data in June. Shares of Trevi (NASDAQ:TRVI) closed July 17 at $19.07, up $1.71, or 9.9%. London-based GSK reported findings with camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. The first met its primary endpoint, with camlipixant 50 mg twice daily showing statistically significant reductions in 24-hour cough frequency vs. placebo when measured at week 12.

Rebates on sales of patented drugs in Germany are to increase from 7% to 15.5%, following passage of an act to reduce healthcare spending across the board. There also will be a 9% rebate on patented vaccines, whilst at the same time prices will be frozen until 2030 and price-volume controls will be introduced to restrict the amount spent overall.

There is no doubt that investment into women’s health is increasing. According to a new report by W Group, in 2025, $1.55 billion in disclosed equity was raised by 85 women’s health companies, across more than 30 countries. However, challenges remain.

Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the integration of Webbiobank, its proprietary cloud-based neural data platform.